著者
岡田 只士 榊 利之 橘高 敦史
出版者
富山県立大学
雑誌
基盤研究(C)
巻号頁・発行日
2020-04-01

近年、血中ビタミンD(VD)濃度が炎症性腸疾患(IBD)症状の悪性化リスクと強く関連することが報告されている。本研究ではVDとIBDとの関係性を、動物モデルを使用して広く解析し、VDをIBDの治療や予防に活用することを目的とする。具体的には、①腸炎モデルにVDを投与し、VDの IBDに対する治療効果や医薬品応用への可能性を検討する、②VD欠乏モデルの消化管病態を解析し、IBD病態とVDとの関りを理解する、という二つの視点から研究を遂行する。 上記の研究を通して、食事やサプリメントによるVD摂取をIBDの治療や予防に繋げ ることを最終目標に本研究を推進する。
著者
榊 利之 安田 佳織 西川 美宇 生城 真一
出版者
公益社団法人 日本薬学会
雑誌
YAKUGAKU ZASSHI (ISSN:00316903)
巻号頁・発行日
vol.138, no.3, pp.357-363, 2018-03-01 (Released:2018-03-01)
参考文献数
22
被引用文献数
2 9

Sesamin, derived from sesame seeds, is known to have various biological effects. Since some of these effects appear to be derived from its metabolites, the elucidation of sesamin metabolism is essential to understanding the molecular mechanism of its effects. In addition, it is important to clarify drug-sesamin interactions in order to address safety concerns, as some food factors are known to affect drug metabolism. Our previous studies revealed that sesamin was sequentially metabolized by cytochrome P450 (CYP) and UDP-glucuronosyltransferase or sulfotransferase. Whereas sesamin metabolism is mainly mediated by CYP2C9 in human liver, sesamin causes a mechanism-based inhibition (MBI) of CYP2C9. However, we found that the metabolite-intermediate complex between CYP2C9 and sesamin was unstable, and the effects of sesamin appeared to be minimal. To confirm this assumption, in vivo studies using rats were conducted. After the administration of sesamin to rats for 3 d, diclofenac (an NSAID) was administered to measure the time course of plasma concentration of diclofenac. No significant differences were observed in the diclofenac Cmax, Tmax, and AUC0-24 h between the group that was administered sesamin and the group that was not. Based on these results, it could be concluded that no significant interaction occurs in people who take sesamin supplements at a standard dose.